Bruno Ravoninjatovo

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Pierre‐Régis Burgel, I. Durieu, R. Chiron et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 227 citations

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

Pierre‐Régis Burgel, À. Munck, I. Durieu et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 127 citations

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon et al. · The Lancet Respiratory Medicine · 2024 · 36 citations · Full text

F508del Cftr Variant, Translational Research, Pulmonary Fibrosis +2

Health-Related Quality of Life in Adults with Cystic Fibrosis: Familial, Occupational, Social, and Mental Health Predictors

Julien Ancel, Claire Launois, Jeanne‐Marie Perotin et al. · Healthcare · 2022 · 19 citations · Full text

Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study

Laurent Meijer, Geneviève Héry-Arnaud, Cyril Leven et al. · Journal of Cystic Fibrosis · 2021 · 17 citations

Antimicrobial Stewardship, Cystic Fibrosis Patients, Pharmacology +7